Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy

Francis Vekeman, Wendy Y. Cheng, Medha Sasane, Lynn Huynh, Mei Sheng Duh, Carole Paley, Ruben A. Mesa

Research output: Contribution to journalArticle

1 Scopus citations


Iron chelation therapies (ICTs) can help eliminate iron surplus in erythrocyte transfusion-dependent (TD) patients with myelofibrosis (MF). The study assessed adjusted incidence rate ratios (aIRRs) of MF-related complications and resource utilization (RU) and adjusted mean monthly inpatient cost differences in patients with TD MF treated with versus without ICT (ICT+ vs. ICT-) using data from two healthcare claims databases. Patients with ≥ 2 MF International Classification of Diseases, 9th Revision (ICD-9) diagnosis codes ≥ 30 days apart were included. Among 571 patients with TD MF, 103 (18%) were ICT+ and 468 (82%) were ICT-. ICT+ patients had lower rates of thrombocytopenia (aIRR: 0.55; p <0.001), pancytopenia (0.53; p <0.001), emergency room visits (0.84 [95% confidence interval: 0.74-0.96]) and inpatient stays (0.75 [0.64-0.87]), but higher rates of outpatient visits (1.21 [1.18-1.23]). Adjusted mean complication-related inpatient cost difference per month was lower in ICT+ patients (-$1804 [$570]; p = 0.004). ICT+ patients had significantly lower rates of acute care, but higher rates of outpatient care.

Original languageEnglish (US)
Pages (from-to)2803-2811
Number of pages9
JournalLeukemia and Lymphoma
Issue number10
StatePublished - Oct 3 2015



  • economic cost
  • iron chelation therapy
  • medical resource utilization
  • Myelofibrosis
  • transfusion dependent

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this